Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Latest news from FRONTIER, the trial investigating the potential of the radiotracer Fluciclovine in the subtyping and staging of breast cancers

Cross-section scan of a patient's abdomen. The breast cancer appears in bright colours as a result of the new technology

PET-CT scans use a special camera combined with small amounts of radioactive materials called radiotracers to image different types of cancer. PET-CT scans are used widely in cancer hospitals to assess the stage of a patient’s tumour, whether the patient is responding to treatment and in some cases what treatment to give.

In the clinic, the radiotracer links radioactivity to sugar, a tracer known as fluorodeoxyglucose or FDG. As cancers are especially hungry for nutrients including sugar to help them grow and proliferate, they take up more of this radioactive sugar than surrounding tissues and thereby ‘light’ up on the PET scan images.

New radiotracers are now being developed which may give us different information about a tumour. One of these new tracers is Fluciclovine (18F), a drug which links radioactivity to a tumour’s consumption of amino acids rather than sugar. This is because amino acids are also taken up in large quantities by cancer cells to help them grow and proliferate.

The breast cancer trial FRONTIER has been investigating the potential of Fluciclovine to help provide information on the underlying character of breast tumours. Fluciclovine is already used to identify recurrent prostate cancer, and one of the objectives of FRONTIER is to see if Fluciclovine works in breast cancers as it does in prostate. It is hoped that it may help distinguish between different breast cancer receptor subtypes. Additionally, the study also attempts to understand if particular genetic switches are turned on in the tumour which might allow us to use this imaging technique to pick out the right treatment for patients.

For example understanding if a tumour prefers amino acids over sugar could be important in deciding what treatment to use, such as those that inhibit the metabolism of the amino acid, glutamine, in tumours. Drugs which target the glutamine metabolism pathway in cancer cells are already in clinical development, such as GLUD, GLS or IDH inhibitors.

Results from the FRONTIER study are expected later this year, and we hope it will be a step towards helping clinicians to improve the staging of a patient’s breast cancer and identifying which patients will benefit most from different treatments.


An example of how Fluciclovine appears in colour on PET-CT scans, with yellow arrows pointing towards the tumourAn example of how Fluciclovine appears in colour on PET-CT scans, with yellow arrows pointing towards the tumour


About this study

The FRONTIER study began in March 2017 to investigate the efficacy of Fluciclovine as a radiotracer in 40 breast cancer patients.

Dr Simon Lord’s work focuses on the development of new drugs to treat breast cancer. He also leads a number of clinical studies assessing how novel metabolic imaging signatures may reflect tumour biology.

The study is co-led by Dr Simon Lord, alongside Prof Adrian Harris & Prof Fergus Gleeson, Dept of Oncology. It is funded by the Oxford Cancer Imaging Centre and the CRUK Oxford Centre. Fluciclovine supply was supported by Blue Earth Diagnostics.

This study is sponsored by the University of Oxford and managed by the Oncology Clinical Trials Office.

Similar Stories

Oxford Cancer: 5 minutes with Professor Dame Molly Stevens

Professor Dame Molly Stevens is John Black Professor of Bionanoscience in the Department of Physiology, Anatomy and Genetics and the Institute of Biomedical Engineering. She recently moved her lab from Imperial College London to the University of Oxford and the Kavli Institute for nanoscience discovery, and she is joining the Oxford Cancer community.